Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Trial of Afatinib (BIBW 2992) + Cetuximab in Advanced Solid Tumours

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02020577
Recruitment Status : Completed
First Posted : December 25, 2013
Results First Posted : February 12, 2016
Last Update Posted : June 22, 2017
Sponsor:
Information provided by (Responsible Party):
Boehringer Ingelheim

Brief Summary:
The trial is divided in two parts, Part A and Part B. Part A will involve dose-finding of dose-limiting toxicity (DLT) and MTD in patients with advanced solid tumours. Part B will involve expansion of the MTD to 3 cohorts including non-small cell lung cancer squamous histology, recurrent/ metastatic squamous cell carcinoma of head and neck and other advanced solid tumours (except sarcomas).

Condition or disease Intervention/treatment Phase
Neoplasms Drug: Cetuximab( erbitux®) Drug: Afatinib Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 58 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase Ib Dose Escalation Study of Afatinib in Combination With Cetuximab in Patients With Advanced Solid Tumours
Study Start Date : December 2013
Actual Primary Completion Date : January 2015
Actual Study Completion Date : April 2016

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: combination arm
Patients to receive afatinib once daily plus weekly cetuximab infusion
Drug: Cetuximab( erbitux®)
once per week

Drug: Afatinib
once per day




Primary Outcome Measures :
  1. MTD of Afatinib in Combination With Cetuximab Based on the Number of Patients With DLTs During the First Treatment Cycle (Afatinib). [ Time Frame: First 21 days treatment cycle ]
    Maximum Tolerated Dose (MTD) of Afatinib in combination with cetuximab based on the number of patients with dose limiting toxicity (DLT) during the first treatment cycle (Dose escalation part). The MTD is defined as the highest dose level at which less than 33% of the patients experience DLT in first treatment cycle.

  2. Dose Limiting Toxicities During Cycle 1 [ Time Frame: First 21-day treatment cycle ]

    Number of Patients With Dose Limiting Toxicity (DLT) Occurring during Cycle 1. The following drug related AEs qualified as DLT:

    1) CTCAE Grade ≥2 decrease in cardiac left ventricular function 2) CTCAE Grade 2 diarrhoea lasting for ≥7 days, despite appropriate use of standard antidiarrheal therapy based on Protocol Amendment 1 dated 22 Oct 2013 3) CTCAE Grade ≥3 diarrhoea despite appropriate use of standard anti-diarrheal therapy for at least 2 days. 4) CTCAE Grade ≥3 nausea and/or vomiting despite appropriate use of standard anti-emetics for at least 3 days 5) CTCAE Grade ≥3 rash despite standard medical management. 6) CTCAE Grade ≥3 fatigue lasting more than 7 days. 7) All other AEs of CTCAE Grade ≥3 (except alopecia and allergic reaction) that led to an interruption of afatinib and/or cetuximab dosing for more than 14 days until recovery to baseline or Grade 1, whichever was higher. 8) CTCAE Grade 4 hypomagnesemia or Grade 3 hypomagnesemia with clinically-significant sequelae


  3. MTD of Afatinib in Combination With Cetuximab Based on the Number of Patients With DLTs During the First Treatment Cycle (Cetuximab). [ Time Frame: First treatment cycle ]
    Maximum Tolerated Dose (MTD) of Afatinib in combination with cetuximab based on the number of patients with DLTs during the first treatment cycle (Dose escalation part).


Secondary Outcome Measures :
  1. Dose Limiting Toxicities During All Treatment Cycles [ Time Frame: All treatment cycle (each treatment cycle of 21 days) ]
    Number of patients with DLT occuring during all treatment cycle is presented

  2. Recommended Phase II Dose Based on the Number of Patients With Dose Limiting Toxicity Events (Cetuximab) [ Time Frame: All treatment cycle (each treatment cycle of 21 days) ]
    MTD was deemed the recommended Phase II dose based on the number of patients with dose limiting toxicity events at all treatment cycles.

  3. Best Overall Response [ Time Frame: Post baseline tumour-imaging was performed at every 6 weeks (in the week preceding the start of Cycles 3, 5, 7, 9, 11, etc.) until EOT; up to 19 months ]

    Best overall response (according to RECIST version 1.1) was defined as the best response recorded at any time from the first administration of afatinib or cetuximab to the End of Treatment (EOT).

    As Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI:

    Complete Response (CR), disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; progression, as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions; Stable Disease (SD), neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for disease progression.


  4. Objective Response [ Time Frame: Post baseline tumour-imaging was performed at every 6 weeks (in the week preceding the start of Cycles 3, 5, 7, 9, 11, etc.) until EOT; up to 19 months ]

    Objective response was defined as the proportion of patients with measurable disease having at least a best overall response of complete response (CR) or partial response (PR), according to RECIST version 1.1.

    As Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI:

    Complete Response (CR), disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; progression, as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions; Stable Disease (SD), neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for disease progression.


  5. Disease Control Rate [ Time Frame: Post baseline tumour-imaging was performed at every 6 weeks (in the week preceding the start of Cycles 3, 5, 7, 9, 11, etc.) until EOT; up to 19 months ]

    For patients with measurable disease, disease control was defined as the proportion of patients having at least a best overall response of CR, PR or stable disease (SD).

    As Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI:

    Complete Response (CR), disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; progression, as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions; Stable Disease (SD), neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for disease progression


  6. Recommended Phase II Dose Based on the Number of Patients With Dose Limiting Toxicity Events (Afatinib) [ Time Frame: All treatment cycle (each treatment cycle of 21 days) ]
    MTD was deemed the recommended Phase II dose based on the number of patients with dose limiting toxicity events at all treatment cycles.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

Part A only

  1. Patients must have advanced malignant solid tumours that are metastatic or unresectable
  2. At least one measurable or evaluable (non-measurable) lesion per RECIST 1.1 Part B only
  3. Patients must have:

    1. measurable disease per RECIST 1.1
    2. diagnosis of one of the following

      • Advanced Non-Small Cell Lung Cancer -Squamous Histology (NSCLC-SQ) with no more than 2 lines of chemotherapy for advanced/metastatic disease ( prior EGFR directed treatment is permitted) or
      • Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck (R/M SCCHN) no more than 2 lines of chemotherapy for advanced disease and no more than 1 line of prior cetuximab permitted.

    or

    • Other malignant solid tumours except sarcomas (for metastatic colorectal cancer, only wild type KRAS are permitted) Part A and B
  4. Age 18 years or older
  5. Written informed consent that is consistent with ICH-GCP guidelines and local law.
  6. Histological/Cytological confirmed diagnosis of malignant solid tumours (exclusion of sarcomas)
  7. Advanced disease for whom standard treatment is ineffective or no longer effective
  8. Recovered from previous therapy related AE to </= Grade 1 at the study entry (except, for stable sensory neuropathy </= Grade 2 and alopecia)
  9. Eastern Cooperative Oncology Group (ECOG) performance score 0 or 1.
  10. Adequate organ function as defined by the following criteria:

    • LVEF >50% or within institutional values
    • Absolute neutrophil count (ANC) >1500/ mm3
    • Platelet count >75.000/ mm3
    • Estimated creatinine clearance > 45ml/ min
    • Total bilirubin<1.5 times upper limit of institutional normal
    • Aspartate amino transferase (AST) or alanine amino transferase (ALT) <3 x upper limit of institutional normal (ULN) (if related to liver metastases< 5xULN)

Exclusion criteria:

  1. Chemotherapy, biological therapy or investigational agents within 4 weeks prior to the start of study treatment.
  2. Hormonal anti-cancer treatment within 2 weeks prior to the start of study treatment (continued use of anti-androgens and/or gonadorelin analogues [LHRH] is permitted)
  3. Radiotherapy within 4 weeks prior to the start of study treatment, except as follows:

    1. Palliative radiation to target organs other than chest may be allowed up to 2 weeks prior to study treatment, and
    2. Single dose palliative treatment for symptomatic metastasis outside above allowance to be discussed with sponsor prior to enrolling.
  4. Major surgery (as judged by the investigator) within 4 weeks before starting study treatment or scheduled for surgery during the projected course of the study
  5. Known hypersensitivity to afatinib or the excipients of any of the trial drugs
  6. History or presence of clinically relevant cardiovascular abnormalities such as uncontrolled hypertension, congestive heart failure NYHA classification of 3, unstable angina or poorly controlled arrhythmia as determined by the investigator. Myocardial infarction within 6 months prior start treatment.
  7. Female patients of childbearing potential who:

    1. are nursing or
    2. are pregnant or
    3. are not using an acceptable method of birth control or do not plan to continue using this method throughout the study and/or do not agree to submit to pregnancy testing required by this protocol.
  8. Any history of or concomitant condition that, in the opinion of the Investigator, would compromise the patient's ability to comply with the study or interfere with the evaluation of the efficacy and safety of the test drug
  9. Previous or concomitant malignancies at other sites, except effectively treated non-melanoma skin cancers, carcinoma in situ of the cervix, ductal carcinoma in situ or effectively treated malignancy that has been in remission for more than 3 years and is considered to be cured.
  10. Requiring treatment with any of the prohibited concomitant medications listed in the protocol that can not be stopped for the duration of trial participation
  11. Known pre-existing interstitial lung disease
  12. Any history or presence of poorly controlled gastrointestinal disorders that could affect the absorption of the study drug (e.g. Crohn's disease, ulcerative colitis, chronic diarrhea, malabsorption)
  13. Active hepatitis B infection (defined as presence of HepB sAg and/ or Hep B DNA), active hepatitis C infection (defined as presence of Hep C RNA) and/or known HIV carrier.
  14. Prior participation in an afatinib clinical study, even if not assigned to afatinib treatment.
  15. Meningeal carcinomatosis
  16. Patients with brain or subdural metastases are not eligible, unless they have completed local therapy and have discontinued the use of corticosteroids or have been on stable dose of corticosteroids for at least 4 weeks before starting study treatment. Any symptoms attributed to brain metastases must be stable for at least 4 weeks before starting study treatment.
  17. Any SPC listed contra-indications for cetuximab
  18. Use of alcohol or drugs incompatible with patient participation in the study in the investigator's opinion.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02020577


Locations
Layout table for location information
France
1200.122.33001 Boehringer Ingelheim Investigational Site
Villejuif Cedex, France
Spain
1200.122.34001 Boehringer Ingelheim Investigational Site
Madrid, Spain
Sponsors and Collaborators
Boehringer Ingelheim
Investigators
Layout table for investigator information
Study Chair: Boehringer Ingelheim Boehringer Ingelheim
Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Boehringer Ingelheim
ClinicalTrials.gov Identifier: NCT02020577    
Other Study ID Numbers: 1200.122
2012-005230-10 ( EudraCT Number: EudraCT )
First Posted: December 25, 2013    Key Record Dates
Results First Posted: February 12, 2016
Last Update Posted: June 22, 2017
Last Verified: May 2017
Additional relevant MeSH terms:
Layout table for MeSH terms
Cetuximab
Afatinib
Antineoplastic Agents, Immunological
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action